Category: Prostate Cancer

Prostate cancer trials often prioritize long-term survival data, but some experts say this narrow focus slows innovation and overlooks the patient experience. A growing call for change highlights the need for shorter, patient-centered studies that measure progress while protecting quality of life. keep reading

For decades, standard TRUS biopsies relied on 12+ random needles—missing aggressive cancers up to 46% of the time and increasing risks of infection. Today, real-time MRI-guided biopsies use just 2–4 precisely targeted needles, giving doctors clearer answers with fewer side effects. Discover why MRI-guided precision is changing prostate cancer diagnosis. keep reading

Gleason 3+3 prostate cancer is often considered low-risk—so low that some experts say it shouldn’t even be called cancer at all. But could a new label change how patients view their diagnosis and choices? The answer may reshape the future of prostate cancer care. keep reading

Gleason 6 prostate cancer has long sparked debate: is it really “cancer” if it rarely spreads? While many experts argue it’s essentially harmless, new research suggests that certain biopsy findings may predict higher risk. Here’s what men on Active Surveillance need to know. keep reading

Prostate cancer cells thrive on testosterone. Hormone therapy works by depriving them of this fuel, slowing disease progression. But ADT also impacts men’s bodies and emotions. Encouraging new research highlights how exercise may counteract these effects. keep reading

When it comes to prostate cancer, risk assessment has to be “just right.” New research shows that combining PSA density with MRI scoring (PI-RADS) makes predictions far more accurate, reducing unnecessary biopsies while ensuring dangerous cancers aren’t missed. keep reading

Active Surveillance helps men with low-risk prostate cancer avoid overtreatment, but anxiety and repeated biopsies can take a toll. A new approach—Super Active Surveillance—combines MRI monitoring with focal therapy, offering peace of mind while keeping future treatment options open. keep reading

A recent study confirms that the new PI-FAB scoring system is highly reliable for evaluating MRI scans after focal therapy. With strong agreement among radiologists, PI-FAB offers patients and clinicians more confidence in long-term monitoring and peace of mind. keep reading

Your gut biome does more than aid digestion—it could influence your risk of cancer and your body’s response to treatment. Discover how trillions of microscopic organisms in your gut may be quietly shaping your prostate health—and what you can do to support them. keep reading

Overtreatment of low-risk prostate cancer can leave men with lasting side effects from unnecessary whole-gland treatment. Today, advances like multiparametric MRI, active surveillance, and focal therapy are offering safer, smarter alternatives that protect health and preserve quality of life. keep reading